secwatch.observer — SEC 8-K summary
======================================

Issuer:     ZEVRA THERAPEUTICS, INC. (ZVRA)
CIK:        0001434647
Form:       8-K
Filed at:   2023-11-07T23:59:59+00:00
Accession:  0001437749-23-030485
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Zevra Therapeutics Q3 net loss widens to $14M; arimoclomol NDA resubmission on track
--------------------------------------------------------------------------------

- Net revenue flat at $2.9M; net loss ($0.40/share) vs ($0.19) in prior year.
- Arimoclomol NDA resubmission for NPC on track by end of 2023; six-month FDA review expected if Type II.
- Proposed Acer acquisition (OLPRUVA, EDSIVO) on track for Q4 close; Acer shareholder vote Nov 8, 2023.
- Neil McFarlane named President and CEO effective Oct 10, 2023.
- Cash $83.4M; cash runway into 2026 includes NDA resubmission and KP1077 program.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1434647/000143774923030485/0001437749-23-030485-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1434647/000143774923030485/zvra20230816_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-23-030485

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer